9.00
price up icon8.70%   0.72
pre-market  Pre-mercato:  9.55   0.55   +6.11%
loading
Precedente Chiudi:
$8.28
Aprire:
$8.15
Volume 24 ore:
43,112
Relative Volume:
0.45
Capitalizzazione di mercato:
$83.27M
Reddito:
-
Utile/perdita netta:
$-6.42M
Rapporto P/E:
-1.6068
EPS:
-5.6013
Flusso di cassa netto:
$-7.45M
1 W Prestazione:
-9.46%
1M Prestazione:
+28.21%
6M Prestazione:
+20.32%
1 anno Prestazione:
-7.22%
Intervallo 1D:
Value
$8.15
$9.02
Intervallo di 1 settimana:
Value
$7.80
$10.00
Portata 52W:
Value
$1.80
$16.94

Cervomed Inc Stock (CRVO) Company Profile

Name
Nome
Cervomed Inc
Name
Telefono
(617) 744-4400
Name
Indirizzo
20 PARK PLAZA, BOSTON
Name
Dipendente
15
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-11
Name
Ultimi documenti SEC
Name
CRVO's Discussions on Twitter

Confronta CRVO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CRVO
Cervomed Inc
9.00 76.61M 0 -6.42M -7.45M -5.6013
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.26 117.50B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
722.83 76.06B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.56 62.53B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
916.31 56.75B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
205.04 44.10B 447.02M -1.18B -906.14M -6.1812

Cervomed Inc Stock (CRVO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-13 Aggiornamento Chardan Capital Markets Neutral → Buy
2024-12-17 Downgrade H.C. Wainwright Buy → Neutral
2024-12-11 Downgrade Chardan Capital Markets Buy → Neutral
2024-12-11 Downgrade Morgan Stanley Overweight → Underweight
2024-12-10 Downgrade D. Boral Capital Buy → Hold
2024-12-06 Iniziato ROTH MKM Buy
2024-12-05 Iniziato H.C. Wainwright Buy
2024-09-18 Iniziato Chardan Capital Markets Buy
2024-07-26 Iniziato Morgan Stanley Overweight
2024-02-15 Iniziato Canaccord Genuity Buy
2020-11-17 Downgrade H.C. Wainwright Buy → Neutral
2018-03-21 Iniziato H.C. Wainwright Buy
Mostra tutto

Cervomed Inc Borsa (CRVO) Ultime notizie

pulisher
02:14 AM

Why CervoMed Inc. (DP8) stock is a strong analyst pickEarnings Performance Report & Risk Managed Trade Strategies - Newser

02:14 AM
pulisher
Dec 04, 2025

CervoMed’s DLB drug shows promise in phase 2b trial - Investing.com

Dec 04, 2025
pulisher
Dec 04, 2025

Cervomed (CRVO) Unveils Promising Phase 2b Trial Results for Nef - GuruFocus

Dec 04, 2025
pulisher
Dec 04, 2025

CervoMed stock soars after promising dementia drug trial results - Investing.com

Dec 04, 2025
pulisher
Dec 04, 2025

CervoMed Inc. Reports Phase 2b RewinD-LB Trial Results for Neflamapimod, Showing Significant Improvements in Dementia with Lewy Bodies Patients - Quiver Quantitative

Dec 04, 2025
pulisher
Dec 04, 2025

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies - GlobeNewswire Inc.

Dec 04, 2025
pulisher
Dec 04, 2025

How rising interest rates impact CervoMed Inc. stockPortfolio Value Report & Safe Swing Trade Setups - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

Is CervoMed Inc. stock attractive after correctionJuly 2025 Action & Fast Exit and Entry Strategy Plans - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

What RSI levels show for CervoMed Inc. (DP8) stockPortfolio Update Report & Low Drawdown Investment Strategies - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

Why CervoMed Inc. (DP8) stock stays undervaluedM&A Rumor & Short-Term High Return Strategies - Newser

Dec 04, 2025
pulisher
Dec 03, 2025

CervoMed's (CRVO) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat

Dec 03, 2025
pulisher
Dec 02, 2025

CervoMed (CRVO) Maintains Buy Rating with Target Price of $31 | - GuruFocus

Dec 02, 2025
pulisher
Dec 02, 2025

CervoMed (CRVO) Unveils Promising Phase 2b Trial Results for Alz - GuruFocus

Dec 02, 2025
pulisher
Dec 02, 2025

Neflamapimod reduces key neurodegeneration markers in DLB study By Investing.com - Investing.com UK

Dec 02, 2025
pulisher
Dec 02, 2025

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB) - Sahm

Dec 02, 2025
pulisher
Dec 02, 2025

How CervoMed Inc. (DP8) stock gains from tech spending2025 Volume Leaders & Free Real-Time Volume Trigger Notifications - Newser

Dec 02, 2025
pulisher
Dec 02, 2025

Will CervoMed Inc. (DP8) stock benefit from Fed rate cutsShare Buyback & AI Powered Market Entry Ideas - Newser

Dec 02, 2025
pulisher
Nov 27, 2025

What analyst consensus says on CervoMed Inc. stockRecession Risk & Free Fast Gain Swing Trade Alerts - BỘ NỘI VỤ

Nov 27, 2025
pulisher
Nov 26, 2025

CervoMed Inc. (CRVO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Nov 26, 2025
pulisher
Nov 26, 2025

CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - ADVFN

Nov 26, 2025
pulisher
Nov 26, 2025

CervoMed Inc Stock Analysis and ForecastVolume Profile Analysis & Explosive Profit Growth - earlytimes.in

Nov 26, 2025
pulisher
Nov 24, 2025

CervoMed Inc. to Present Phase 2b Trial Results of Neflamapimod for Dementia with Lewy Bodies at CTAD Conference - Quiver Quantitative

Nov 24, 2025
pulisher
Nov 24, 2025

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference - Sahm

Nov 24, 2025
pulisher
Nov 19, 2025

CervoMed Executives Make Bold Moves with Major Stock Purchases! - TipRanks

Nov 19, 2025
pulisher
Nov 19, 2025

Will CervoMed Inc. stock outperform Nasdaq indexWeekly Gains Summary & Free Technical Pattern Based Buy Signals - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

CervoMed Inc. Stock (CRVO) Opinions on Insider Buying and Clinical Trial Progress - Quiver Quantitative

Nov 19, 2025
pulisher
Nov 19, 2025

CervoMed Inc. stock retracement – recovery analysisChart Signals & Smart Money Movement Tracker - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Will CervoMed Inc. (DP8) stock deliver compounding returns2025 Top Decliners & Verified Swing Trading Watchlist - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

CervoMed Inc.: Chief commercial officer Winton buys $41k in CRVO - Investing.com Australia

Nov 19, 2025
pulisher
Nov 19, 2025

CervoMed CEO Alam buys shares worth $182,736 By Investing.com - Investing.com Australia

Nov 19, 2025
pulisher
Nov 19, 2025

Elder William buys CervoMed (CRVO) stock worth $29,250 By Investing.com - Investing.com Canada

Nov 19, 2025
pulisher
Nov 19, 2025

Insider Buying: Matthew Winton Acquires Additional Shares of Cer - GuruFocus

Nov 19, 2025
pulisher
Nov 19, 2025

Gregoire Sylvie buys CervoMed (CRVO) shares worth $182,736 By Investing.com - Investing.com Canada

Nov 19, 2025
pulisher
Nov 19, 2025

CervoMed Inc.: Chief commercial officer Winton buys $41k in CRVO By Investing.com - Investing.com South Africa

Nov 19, 2025
pulisher
Nov 19, 2025

Elder William buys CervoMed (CRVO) stock worth $29,250 - Investing.com

Nov 19, 2025
pulisher
Nov 19, 2025

CervoMed CEO Alam buys shares worth $182,736 - Investing.com India

Nov 19, 2025
pulisher
Nov 19, 2025

Tools to monitor CervoMed Inc. recovery probabilityJuly 2025 Recap & AI Based Trade Execution Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

[Form 4] CervoMed Inc. Insider Trading Activity - Stock Titan

Nov 19, 2025
pulisher
Nov 19, 2025

How to integrate CervoMed Inc. into portfolio analysis toolsMarket Growth Summary & Real-Time Chart Breakout Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

CervoMed Inc. stock trend outlook and recovery pathTake Profit & Fast Exit/Entry Strategy Plans - newser.com

Nov 19, 2025

Cervomed Inc Azioni (CRVO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$39.16
price down icon 1.10%
$100.48
price down icon 1.00%
$32.03
price up icon 1.10%
$95.99
price down icon 0.77%
biotechnology ONC
$331.27
price down icon 1.95%
$205.04
price down icon 0.84%
Capitalizzazione:     |  Volume (24 ore):